Health benefits platform Thatch reaches $1B valuation as healthcare costs surge
TechCrunch
β’Tue, 15 Sep 2026 17:02:04 +0000
π° What Happened
Thatch, a platform that lowers healthcare costs for employers while expanding plan choices for workers, raised $108 million at a $1 billion valuation from existing investors The General Partnership, Index Ventures, General Catalyst and Andreessen Horowitz. The round comes 17 months after a $40 million Series B at a $410 million valuation, according to PitchBook, and co-founder and CEO Chris Ellis told TechCrunch that the company grew its annual recurring revenue roughly seven times. Thatch was founded in 2021 by Ellis and former Stripe engineering executive Adam Stevenson and operates through ICHRAs, Individual Coverage Health Reimbursement Arrangements, a model created by federal regulation in 2020 that lets employers fund employees' own individual insurance plans instead of enrolling everyone in one company-wide plan; ICHRAs have recently been rebranded as CHOICE. The article points to two forces driving growth: employer healthcare costs projected to jump over 8 percent for 2027, the largest increase since 2003, and rising employee demand for treatments such as GLP-1 drugs that traditional plans rarely cover.
π The Backstory
The US employer-sponsored insurance system ties coverage to a company-wide plan, and costs have climbed faster than wages for years, pushing some employers toward defined-contribution-style alternatives. The ICHRA structure was created by federal regulation in 2020 to let employers reimburse workers for individually purchased coverage, opening a market for platforms that administer the arrangements and help employees shop. Thatch's backers are betting the model scales as plan costs accelerate.
π― Why It Matters
The funding round signals that investors see individual-market administration as a growth area as employer health costs accelerate. For employers, ICHRAs promise more predictable spending, but they shift more responsibility for choosing and affording coverage onto workers, and those with costly conditions or limited plan options may fare worse. Employees seeking newer treatments such as GLP-1 drugs are a particular flashpoint, since individual plans vary widely in whether they cover them. Whether the model improves health outcomes as well as controlling costs will be the central policy question as it spreads.
Thatch, a platform that lowers healthcare costs for employers while expanding plan choices for workers, raised $108 million at a $1 billion valuation from existing investors The General Partnership, Index Ventures, General Catalyst and Andreessen Horowitz. The round comes 17 months after a $40 million Series B at a $410 million valuation, according to PitchBook, and co-founder and CEO Chris Ellis told TechCrunch that the company grew its annual recurring revenue roughly seven times. Thatch was founded in 2021 by Ellis and former Stripe engineering executive Adam Stevenson and operates through ICHRAs, Individual Coverage Health Reimbursement Arrangements, a model created by federal regulation in 2020 that lets employers fund employees' own individual insurance plans instead of enrolling everyone in one company-wide plan; ICHRAs have recently been rebranded as CHOICE. The article points to two forces driving growth: employer healthcare costs projected to jump over 8 percent for 2027, the largest increase since 2003, and rising employee demand for treatments such as GLP-1 drugs that traditional plans rarely cover.
The US employer-sponsored insurance system ties coverage to a company-wide plan, and costs have climbed faster than wages for years, pushing some employers toward defined-contribution-style alternatives. The ICHRA structure was created by federal regulation in 2020 to let employers reimburse workers for individually purchased coverage, opening a market for platforms that administer the arrangements and help employees shop. Thatch's backers are betting the model scales as plan costs accelerate.
The funding round signals that investors see individual-market administration as a growth area as employer health costs accelerate. For employers, ICHRAs promise more predictable spending, but they shift more responsibility for choosing and affording coverage onto workers, and those with costly conditions or limited plan options may fare worse. Employees seeking newer treatments such as GLP-1 drugs are a particular flashpoint, since individual plans vary widely in whether they cover them. Whether the model improves health outcomes as well as controlling costs will be the central policy question as it spreads.